Introduction
Financial burden of increasing healthcare costs is a significant issue of concern for all segments of society. Organizations and government are ceaselessly confronted with troublesome choices in regards to the allotment of social insurance assets. Not just is cost cognizance imperative, there is likewise a solid need to control healthcare costs and to consider which intercessions deliver the best value, based to some degree on a financial assessment. [1] [2] [3] The importance of cost analysis is being more emphasized recently along with the contexts of monetary examination that considers the relative consumptions and results of two or more procedures that play out the same task. It has been prevalently utilized as a part of different fields in the course of recent decades. 5 Factual strategies for CEA have been created and a measure, the incremental cost efficiency ratio (ICER), has been bolstered by different powers and most broadly received by scientists and policy makers.
Background
Post-operative atrial fibrillation (POAF) happens in 20-50% of patients amid post-operative stay after Cardiac Surgery. It happens in numerous structures from a solitary brief asymptomatic event to a consistent aggravation, obstinate to treatment and connected with major hemodynamic consequences. It is a marker of increased morbidity and mortality. 6 However notwithstanding when it happens as an isolated event, many recent studies have suggested that POAF is an essential determinant of post-operative length of stay (LOS), incremental asset usage, and readmission rates. [7] [8] [9] [10] [11] However the magnitude of this effect has not been well described till date. A superior comprehension is expected to evaluate the effect of POAF on patient outcomes, healthcare resources and services costs. 7, 9 Analyses of such hospital costs have suggested the economic value of this approach from the perspective of the provider (hospital). However, because there is exceptionally constrained information on the full extent of immediate and circuitous expenses with POAF and there has been no clear assessment of the impact of POAF on patient outcome measures, the economic analysis is therefore limited in scope. Various pharmacological and other measures have been under the scanner recently to reduce the POAF associated costs in cardiac surgery patients. Carsten et al. 12 recently published a systematic review of current literature and meta-analysis of all available randomized control trials examining effect of colchicine on prevention of POAF events (see Supplementary material online). Meta-analysis of five randomized controlled trials (RCT)'s using a random-effects model suggested that colchicine significantly reduced the incidence of POAF in patients undergoing cardiac surgery compared with control [risk ratio 0.69, 95% confidence interval (95% CI) 0.57 to 0.84, P < 0.0002]. Colchicine reduced mean LOS by more than 1 day (weighted mean difference -1.01, 95% CI -1.75, 0.26), P = 0.008. The randomized control trials included in the meta-analysis are detailed in Table 1 . Cost calculations referenced under various expense head and time horizon are depicted in Table 2 . Mean follow up costs with future discounting rate @3.5% are also tabulated for 10 years life expectancy in Tables 3 and 4 .
Objective We intend to calculate the cost efficacy of the routine use of colchicine to prevent POAF in unselected patients undergoing cardiac surgery. Based on the recently published results from meta-analysis by Carsten et al. 12 we intend to determine whether colchicine therapy in patients undergoing cardiac surgery is a cost-effective strategy for prevention of POAF. To undertake a cost utility analysis and calculate incremental cost utility ratio (ICUR) for the same.
Methods

Model
Decision tree model to calculate the ICUR. We performed a decision analysis comparing two treatment strategies.
Intervention group: wherein patients were treated with colchicine along with usual post-operative care and, Control group: where they received either a placebo with usual care or just usual care.
Intervention group: Herein patients received prophylactic colchicine therapy for prevention of POAF. The three obvious possibilities were considered. NO POAF group continues usual care. This group develops POAF and continues with usual care along with management of POAF. Adverse effects group can further be subdivided according to the outcomes of (i) not developing POAF and (ii) developing POAF.
However, as this is the control group regardless both continue with usual post-operative care.
Data sources: probability, utility, and cost
Using relevant data from systematic review and meta-analysis by Carsten et al. 12 (systematic review registration number PROSPERO -CRD42016046010) which include all relevant RCTs conducted till June 2016, utility values from EuroQol calculator for UK (EQ-5D based) 18 and cost considerations from relevant data sources 19, 20 
Outcome measures
Quality-adjusted life-years (QALYs) gained on EQ-5D based 18 EuroQol Calculator (ICD-9) and Costs (in Euros) were populated for each group according to the probabilities of the POAF events and ICUR was calculated.
Results
Occurrence of POAF, adverse effects and total hospital LOS were compared between groups. Derived costs were used to calculate the ICUR based on utility values from EuroQol calculator for UK (EQ-5D). 18 The total costs for patients with and without POAF were also compared for in patient expenses and follow-up for 10 years [life expectancy (LE) = 10 years from mean age at surgery]. Therapy is assumed to be 31% effective in preventing episodes of AF based on the meta-analysis. 12 Fewer patients receiving prophylactic colchicine developed POAF compared with controls (18% vs. 27%, P = 0.0002). 12 Patients in the placebo group had a longer mean stay in the hospital by 1.01 days (P = 0.002). 12 Cost-utility was carried out taking a longer-term perspective in terms of cost per QALY gained. This involved calculation and educated assumptions about the effect of post-operative AF on future costs with appropriate discount rate @3.5%, utility and effect of events on utility. Total mean treatment costs for the colchicine group was 4.25% less than those for the control group (e28 893.60 vs. e30 253.15) for LE calculated at 10 years. Colchicine treatment based on mean costs was e 17544.80 cheaper per QALY gained. The incremental cost is negative and the incremental effect (QALY) is positive [South East (SE) quadrant]. Hence the intervention of colchicine treatment is unequivocally costeffective (it is dominant and achieves better outcomes at lower cost). The incremental cost-utility of targeted therapy measured in cost per QALY gained is presented in Figure 1 .
Sensitivity analysis
Sensitivity analysis on change in POAF probabilities and varying costs (mean, minimum, and maximum) were also carried out and yielded similar results. The treatment costs for our intervention is not a major cost (e35/100 tabs) since colchicine is a very old drug and has been used in other inflammatory conditions as gout etc. With change in probabilities of POAF events, assuming maximum reported POAF incidence in literature which is 50% while assuming colchicine to be reducing the POAF rates even much lower say 10% instead of 18% as reported in the meta-analysis 12 the sensitivity analysis still implies that colchicine treatment is cheaper than usual care per QALY gained. The effect of change in prices (up to 3Â current cost) is also not very significant. Neither are the changes in total costs of care for POAF and non-POAF patients over the LE of 10 years. Our extensive analysis implies that whatever the costs of care are in any given jurisdictions for these subsets of patients, the ICUR will always be dominant (SE quadrant) when there is a reduction in POAF event rates by colchicine therapy.
Discussion
Atrial fibrillation is a common occurrence after cardiac surgery, with estimates of incidence ranging from approximately 10% to 50%. Atrial fibrillation has been shown to be associated with prolonged length of hospital stay in various studies. Our analysis shows, that POAF is associated with increased healthcare costs. Although the heart rate of AF can generally be easily controlled pharmacologically and AF can be converted to sinus rhythm both pharmacologically as well as by electrical cardioversion, AF tends to increase the postoperative complications, increased morbidity and mortality and also tends to recur. Furthermore, AF may be complicated by thromboembolic events. Thus, there would seem to be a role for effective prophylactic therapy.
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to study the effects of colchicine therapy in reduction of POAF in patients undergoing cardiac surgery and available cost estimations of post-operative AF, we were able to perform a cost-utility analysis of colchicine therapy in patients undergoing cardiac surgery. The fleeting appraisals regarding cost per episode of AF averted are troublesome if not difficult to benchmark against different sorts of treatment. Nevertheless, the data introduced in our study can be valuable in guiding the basic decision making process. If an acceptable upper limit of cost per episode of AF averted or QALY gained is known, then all patients for whom the prevention cost of an event is less than this upper limit, should receive therapy. Our cost utility analyses suggest that the administration of colchicine to patients undergoing cardiac surgery is cost-effective. In the event that the rate of POAF is higher than that reported in our study, the proportion of patients treated at any given predicted probability threshold would increase. Although this study takes a provider perspective overall, the societal perspectives are also relevant for societal costs. The costeffectiveness ratio should also be viewed from a societal perspective because it is the responsibility of society as a whole to prevent cardiovascular events as ultimately all costs are borne by the society. Therefore, in view of the competition for limited healthcare resources, the consideration of additional healthcare expenditures should be based on the evaluation of whether the additional expense is worthwhile given the benefits accrued; therefore, it is the incremental cost-effectiveness ratios (or ICUR) that must be evaluated with respect to their acceptability in making guidelines and recommendations.
Study limitations
Paucity of articles assessing long term cost ramifications of POAF is a major limitation. This study is constrained by the assumption that costs beyond the initial hospitalization are equivalent in patients who do, or do not develop POAF complications. If the costs for AF induced complications like stroke etc. are considered post-discharge then, the cost-effectiveness of colchicine prophylactic treatment would increase. The extension of the in-hospital cost-effectiveness analysis to a long-term cost-utility analysis involved multiple additional educated assumptions although most cost references are well sourced through literature review. The cost-effectiveness ratio may be quite sensitive to these assumptions and derived costs in multiple jurisdictions. However, with cost-effectiveness expressed in cost per QALY gained, it is conceivable to benchmark the cost-effectiveness of this therapy against other forms of therapy. Probabilities and costs were the two primary variables examined by sensitivity analysis. An additional assumption underlying this model is that the cost of AF in high-risk patients is equivalent to that in low-risk patients.
Conclusions
Our findings provide an 'a la mode' benchmark for current and future analyses relating to effectiveness of colchicine on POAF events after cardiac surgery. More data are still needed to determine the true costs associated with efforts aimed at reducing the incidence of POAF and to clarify the most cost-effective strategies for cardiac surgery patients. Currently, there are few reports that provide cutting edge estimates of the higher expenses associated with POAF. Future analyses should likewise explore the impact of added costs from using pharmacologic efforts to prevent and treat POAF after cardiac surgery. As the level of risk increases, therapy to decrease events can become more financially beneficial. From a societal or policy standpoint, studies such as this may help in the development of informed guidelines for the use of prophylactic therapies.
What is known?
Colchicine therapy reduces the POAF events in cardiac surgery patients due to its putative anti-inflammatory properties. Similar to paroxysmal AF, POAF is associated with an increased burden of cardiovascular comorbidities and cumulative healthcare costs. [23] [24] [25] [26] What this study adds:
• Colchicine therapy is more effective and less costly 'dominant' when compared to usual post-operative care in cardiac surgery patients.
• This decision-analytic modelling study fills a critical gap in the literature by examining the cost-effectiveness of colchicine treatment in patients undergoing cardiac surgery vs. usual post-operative care alone and how that cost-effectiveness varies according to patients' risk of having a POAF event. Figure 1 Calculating incremental cost utility ratio for colchicine treatment in cardiac surgery patients for reduction in post operative atrial fibrillation events. Mean incidental costs plus average follow up costs @ e1750/year (POAF Patients). Discounting rate @ 3.5%.
